A pilot clinical trial (ClinicalTrials.gov identifier, NCT01886976) reported the results of five patients with refractory and relapsed MM, pre-treated with chemotherapy and stem cell transplantation, who received an average dose of 0.756 × 107 cells/kg of autologous CD138 CAR-T cells (Table 2) (32). This evidence concerns the gene SDC1 and Miyoshi myopathy.